Novo Nordisk: obesity drugs priority over century-old focus on insulin https://ift.tt/LdKqmyx

Novo's diabetes drug Ozempic and Wegovy are from the class called GLP-1 receptor agonists, and both contain the active ingredient semaglutide, originally developed to help control blood sugar in patients with diabetes. Ozempic is approved for treatment of type 2 diabetes, while Wegovy is approved for weight loss.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/gWjr8mB
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.